Pharmerging contract manufacturing sales will grow through 2036, led by branded generics at 42.3% of the product segment in 2026, driven by demand for specialized branded generics applications. The market was valued at USD 195.20 billion in 2025 and is expected to be worth USD 402.50 billion by 2036.